Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.
Saved in:
| Title: | Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors. |
|---|---|
| Authors: | Huang W; Genentech Inc, South San Francisco, CA, United States., Stader F; Certara UK Limited, Sheffield, United Kingdom., Chan P; Genentech Inc, South San Francisco, CA, United States., Shemesh CS; Genentech Inc, South San Francisco, CA, United States., Chen Y; Genentech Inc, South San Francisco, CA, United States., Gill KL; Certara UK Limited, Sheffield, United Kingdom., Jones HM; Certara UK Limited, Sheffield, United Kingdom., Li L; Certara UK Limited, Sheffield, United Kingdom., Rossato G; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Wu B; Genentech Inc, South San Francisco, CA, United States., Jin JY; Genentech Inc, South San Francisco, CA, United States., Chanu P; Genentech Inc, South San Francisco, CA, United States. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2022 Sep 26; Vol. 13, pp. 974423. Date of Electronic Publication: 2022 Sep 26 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
